key: cord-0263985-65mmjorw
authors: Bihani, Subhash C; Hosur, Madhusoodan V
title: Molecular Basis for Reduced Cleavage Activity and Drug Resistance in D30N HIV-1 protease
date: 2021-03-01
journal: bioRxiv
DOI: 10.1101/2021.02.28.433284
sha: 684372791a5c14a4fc96673e91c9bbf52f2a9db9
doc_id: 263985
cord_uid: 65mmjorw

Nelfinavir is one of the FDA approved HIV-1 protease inhibitors and is a part of HAART therapy for the treatment of HIV-AIDS. Nelfinavir was the first HIV-1 protease inhibitor to be approved as a Paediatric formulation. The application of HAART had resulted into significant improvement in the life of AIDS patients. However, emergence of drug resistance in HIV-1 protease limited the use of many of these drugs including nelfinavir. A unique mutation observed frequently in patients treated with nelfinavir is D30N as it is selected exclusively by nelfinavir. It imparts very high resistance to nelfinavir but unlike other primary mutations does not give cross resistance to the majority of other drugs. D30N mutation also significantly reduces cleavage activity of HIV-1 protease and affects the viral fitness. Here, we have determined structures of D30N HIV-1 protease in unliganded form and in complex with the drug nelfinavir. These structures provide rationale for reduced cleavage activity and molecular basis of resistance induced by D30N mutation. The loss of coulombic interaction part of a crucial hydrogen bond between the drug and the enzyme, is a likely explanation for reduced affinity and drug resistance towards nelfinavir. The decreased catalytic activity of D30N HIV protease, due to altered interaction with substrates and reduced stability of folding core may be the reasons for reduced replicative capacity of the HIV harboring D30N HIV-1 protease.

Development of HIV-1 protease inhibitors is a successful story of structure-based drug design approach. Introduction of these inhibitors as part of HAART therapy has improved the life of millions of patients. Together with the HIV-1 prevention programs, these drugs have successfully reduced the burden of HIV-1 AIDS on the human population. So far, 8 HIV protease inhibitors have been approved by food and drug administration, USA. All these drugs are competitive inhibitors i.e., their effectiveness is based on balance between their affinity versus that of the substrates in the binding site. Drug resistance mutations against all the approved protease inhibitors have been reported. Many of these drug resistance mutations are known to affect the catalytic efficiency of the enzyme but the effect is more on the inhibitor binding as compared to the substrate. Thus under the selection pressure of these drugs, mutated protease proves advantageous despite altered catalytic proficiency. Also, accessory mutations restores the catalytic activity of the enzyme providing more selective advantage to mutant protease.

Nelfinavir mesylate, Viracept is one of the FDA approved HIV protease inhibitors developed by Agouron Pharmaceuticals using structure based drug design strategy and Monte Carlo simulations [Gehlhaar et al 1995] . Recently, nelfinavir is also shown to be effective against Covid-19 as it inhibits SARS-CoV-2 3CL protease (Jan et al., 2021) . Nelfinavir has also shown anti-cancer properties through its effects on different cellular conditions like cell cycle, apoptosis, autophagy, the proteasome pathway, oxidative stress, the tumor microenvironment, and multidrug efflux pumps (Subeha and Telleria, 2020) . Multiple clinical trials have supported the anticancer applications of nelfinavir with one of the clinical trials showing it as a promising drug for long-term local control and survival in patients with locally advanced non-small cell lung cancer (Rengan et al., 2019) . Nelfinavir has a S-phenyl group at P1 subsite and a novel 2-methyl-3-hydroxy benzamide group at P2 subsite along with a dodecahydroisoquinoline ring at P1' site and tert-butylcarboxamide group at P2' site ( Figure 1 ). Nelfinavir has high affinity towards HIV-1 protease with Ki of 2 nM and was the first protease inhibitor approved for use in pediatric AIDS patients. Nelfinavir has a unique drug resistance mutation pattern in comparison with other FDA approved protease inhibitors. D30N, L90M, and N88S are the major mutations observed against nelfinavir along with many minor mutations including M36I, M46I/L, I54V, A71V, V82A, I84V, and N88D etc [Rhee et al 2003] . These mutations render the drug ineffective and require continuous development of more effective HIV-1 protease inhibitors which needs a clear understanding of the structural effects caused by these drug resistance mutations. For present work, mutations D30N in which an active site aspartate is replaced with asparagine is chosen and their crystal structures both in unliganded form and in complex with the drug nelfinavir were determined. D30N is the most common mutation observed in the 36-59% population of HIV infected patients undergoing nelfinavir therapy [Patick et al 1998 , Yerly et al 2001 , Perrin and Mammano 2003 , Saah et al 2003 . Interestingly, D30N is exclusively selected by nelfinavir and does not provide cross resistance to the majority of other HIV protease inhibitors [Perrin and Mammano 2003] .

D30N mutation leads to~39 fold resistance against nelfinavir as measured by PhenoSense assay [Rhee et al 2003] , while the increase in K i value of approximately 20-fold compared to the wild type is reported [Kozisek et al 2007] . As compared to other HIV protease drug resistance mutations, D30N also has a crippling effect on the catalytic activity of HIV-1 protease with upto 90% loss in the k cat value [Mahalingam et al 1999 , Kozisek et al 2007 . Phage λ based genetic screening method has shown 97.8% loss of proteolytic activity in D30N HIV-1 protease as compared to the wild type HIV-1 protease [Parera et al 2007] . Similarly, highly deleterious effect of D30N on the virus and its replicative capacity has been observed [Martinez-Picado et al 1999] . Earlier a low-resolution structure of D30N HIV-1 protease-nelfinavir complex suggested that reduced binding affinity of nelfinavir is not due to structural changes in the active site pockets [Kozisek et al 2007] .

High-resolution crystal structure of D30N mutant HIV-1 protease will help in understanding the structural effects of D30N, its molecular basis of drug resistance and exclusivity against nelfinavir. Also, there is no structure available for D30N HIV-1 protease in unliganded form, which is important to completely understand the structural effects caused by mutations. This paper reports X-ray crystal structures of D30N HIV-1 protease both in unliganded form and in complex with the drug nelfinavir determined to resolutions of 1.65 Å and 1.91 Å respectively. These structures will provide atomic level details of the structural effects caused by the mutation D30N and also reveal the molecular basis of drug resistance. The information gained will be highly beneficial for modification of nelfinavir to keep it relevant and development of new HIV-1 protease inhibitors. 

The tethered dimer of HIV-1 protease gene described earlier was used as a template to create D30N HIV-1 protease (Bihani et al., 2009; Prashar et al., 2010) . Since HIV-1 protease is active as a homodimer, two HIV-1 protease genes are fused with a GGSSG linker to express it as a tethered dimer. Since there are two chains, mutation has to be introduced in both the chains, hence, the mutations were introduced by Quick-change multisite directed mutagenesis method [Stratagene, La Jolla, CA]. The primer sequence used was 5'-CTGGATACCGGTGCTGAT*A*ATACTGTACTGGAGGAG -3' and was designed

using Primer X software [Lapid 2003 ]. Presence of mutations in the protease gene was confirmed by DNA sequencing and D30N HIV-1 protease gene insert was transformed into E.coli BL21 (DE3) cells. The cells were grown in Luria-Bertani (LB) broth till OD 600 of 0.6-0.8 and protein expression was induced by adding 1 mM IPTG. Cells were harvested after 3-4 hours by centrifugation at 5000 x g for 10 minutes at 4 º C. Temperature for all the subsequent steps was maintained at 4 º C and all the buffers were pre-cooled to 4 º C. The cell pellet were lysed by ultrasonication in lysis buffer (20mM Tris, 10mM EDTA and 1% Triton X-100) in pulse mode (1 sec on and 2 sec off-total 4 minutes pulse on). The lysate was then centrifuged at 10000 x g for 10 minutes. D30N HIV-1 protease accumulated in inclusion bodies, hence, the supernatant was discarded and grayish white pellet of inclusion bodies was retained. The pellet was washed thrice with lysis buffer using ultrasonication and centrifugation to remove all the impurities. The washed pellet which mostly contains pure D30N HIV-1 protease was finally dissolved in 3-4 ml of 67% acetic acid followed by centrifugation at 10000 x g for 15 min. The supernatant was diluted by 33 times with distilled water and dialyzed twice against cold distilled water and finally against ice-cold refolding buffer (20 mM PIPES pH 6.5, 100mM NaCl, 1mM DTT and 10% glycerol). After removing the precipitate by centrifugation at 10000x g for 15 minutes, the purified protein was concentrated by centrifugal concentrators up to the desired concentration. 

The D30N HIV-1 protease unliganded and in complex with nelfinavir were crystallized in P6 1 space group with one tethered dimer in an asymmetric unit. The residues in the first monomer are numbered as 1-99 and those in the second monomer are numbered 1001-1099. 

The clear difference density visible in the active site of D30N-nelfinavir complex structure displayed an approximate two-fold symmetry suggesting that nelfinavir is bound in two orientations corresponding to the pseudo-two fold symmetry of the active site. Therefore, nelfinavir is modeled with two alternate conformations (A and B) (Figure 2 ). The two orientations A and B were included with occupancy of 0.5 each at the start of the refinement which converged to the occupancy of 0.49/0.5 respectively at the end of refinement. 

Simulated annealed OMIT density calculated by omitting either the whole amino acid residue 

Despite having been crystallized in different space groups, D30N-nelfinavir complex structure superposes on wild type-nelfinavir complex structure (PDB ID 3EKX) with RMSD of 0.427Å, suggesting that overall conformation remain same with deviations at D25 Cα positions being less than 0.1Å (0.08/0.05Å). This RMSD of 0.427Å is even less than 0.53Å RMSD between unliganded structures, which were crystallized in the same space groups.

This suggests that there are some differences in the wild type and mutant proteases and those were reduced upon binding to nelfinavir. Interestingly, deviations at D/N30 Cα is 0.05/0.08Å and at side chain ND2/OD2 atoms is 0.17/0.34Å, which is much less than the deviation observed in unliganded structures. Much larger shifts of the order of 0.7 Å-0.8 Å were predicted for these residues by theoretical simulations [Ode et al 2007] . 

The hydrogen bonding interactions (donor-acceptor distance less than 3.2Å) of nelfinavir in the binding cavity of D30N HIV-1 protease are shown in Figure 5 . 

Depending on the orientation of the N30 side chain, there can be two different possibilities of hydrogen bonding in the D30N-nelfinavir complex. In case of preferred rotamer, the drug will be an acceptor in an O…H-N hydrogen bond while in the alternative arrangement, where N30 OD1 atom is towards the drug, it will be a donor in an O-H…O hydrogen bond. Our analysis based on rotamer preference, R-factors and hydrogen bonding interactions suggest that both the orientations may be present at different times as they are equally likely. In both the situations, the nature of hydrogen bond in the mutant as compared to the wild type HIV-1 protease is different. A charged acceptor-neutral donor hydrogen bond interaction in wild type HIV-1 protease is changed to a neutral donor-neutral acceptor interaction in D30N

HIV-1 protease. The free energy change associated with the ionic hydrogen bond of first condition is estimated to be 16-23 kcal/mol which will be greatly reduced to 3-6 kcal/mol in the alternative condition of mutant protease [Rose, 1993] . Therefore, the change in the nature of hydrogen bond is likely to result into a relatively weaker hydrogen bond between nelfinavir 2-methyl-3-hydroxy benzamide group and amide side chain of D30N HIV-1 protease. Overall conformation of nelfinavir in the mutant structure is also slightly altered from the wild type with all the four sub-sites being affected (Figure 4 ). These small changes in the conformation of the drug leads to suboptimal fitting of the drug in the active site of mutant protease. Overall normalized complementarity between nelfinavir and active site calculated using LPC software [Sobolev et al 1999] , is reduced from 0.79 in the wild type 

Mutation D30N leads to substantially reduced cleavage activity of HIV-1 protease and also affects replicative capacity/vitality of the virus. D30 is located in the HIV-1 protease active site and interacts with the peptide substrates through both main chain and side chain atoms interacts with Asp30 side chain (2.9-3.0 Å). In P1-P6, Arg NE also forms hydrogen bonds with Asp30 side chains (3.0-3.2 Å). Mutation D30N is likely to affect these hydrogen bonds and in-turn cleavage process of these substrates will be altered. Any alterations in the cleavage rates will have a large impact on overall fitness of HIV-1 virus. Only three residues D29, D30 and R8 are involved in the side chain hydrogen bonds (less than 3.2Å) with the substrates. Interestingly, all the three residues are absolutely conserved except D30 which mutates under extreme selection pressure of selected drugs particularly nelfinavir. In fact, substrate co-evolution has been observed in HIV-1 protease p1-p6 substrate to compensate for the loss of electrostatic and and hydrogen bonds interactions due to D30N mutation [Kolli et al., 2014] . Thus, overall these altered electrostatic and hydrogen bond interactions are likely to affect the catalytic activity of the enzyme. Residue D30 is part of a structurally conserved loop (24-34) shown to be the part of HIV-1 protease folding core [Wallqvist et al 1998, Broglia et protease. This decreased catalytic activity and reduced stability of folding core due to D30N mutation is suggested as the reason behind reduced replicative capacity of the HIV harboring D30N HIV-1 protease.

Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S

Multiple routes and milestones in the folding of HIV-1 protease monomer

HIV-1 protease folding and the design of drugs which do not create resistance

Coot: Model -building tools for molecular graphics

Features and development of Coot

De novo design of enzyme inhibitors by Monte Carlo ligand generation

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

HIV-1 protease-substrate coevolution in nelfinavir resistance

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V and L90M

Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures and thermodynamics of nelfinavir-resistant HIV protease mutants

PrimerX -Automated design of mutagenic primers for site-directed mutagenesis

Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix

Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1

Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease

Optimal description of a protein structure in terms of multiple groups undergoing TLS motion

HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir

Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants

Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes

Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial

Human immunodeficiency virus reverse transcriptase and protease sequence database

Hydrogen bonding, hydrophobicity, packing and protein engineering

Treatment with Indinavir, Efavirenz, and Adefovir after failure of nelfinavir therapy

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir

Automated analysis of interatomic contacts in proteins

Atomistic simulations of HIV-1 protease folding inhibition

A cooperative folding unit in HIV-1

Implications for protein stability and occurrence of drug-induced mutations

MolProbity: More and better reference data for improved all-atom structure validation

Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation

Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir

We thank late Dr Jean -luc Ferrer, FIP beamline, ESRF, for help in data collection and processing. We also thank the National Facility for Structural Biology for providing the facility to conduct these experiments.